NCT03634345View on ClinicalTrials.gov

Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 12, 2018

Primary Completion Date

December 13, 2018

Study Completion Date

December 13, 2018

Conditions
Dermatitis, Atopic
Interventions
DRUG

Period 1 - Day 1: PF-04965842 administered

Period 1: Single administration of 100 mg PF 04965842.

DRUG

Period 2: Cohort 1: Fluvoxamine & PF-04965842

Cohort 1: Period 2: Administration of fluvoxamine from Day 1 to Day 9 and PF-04965842 on Day 8.

DRUG

Period 2: Cohort 2: Fluconazole & PF-04965842

Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03634345 - Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842. | Biotech Hunter | Biotech Hunter